Title : Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.

Pub. Date : 2010 Mar

PMID : 20197396






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sorafenib-induced decrease in RAF-STC showed statistically significant correlation with time-to-progression in seven patients. Sorafenib zinc fingers and homeoboxes 2 Homo sapiens
2 RAF-STC deserves further study as a predictive marker for sorafenib. Sorafenib zinc fingers and homeoboxes 2 Homo sapiens